ANI Pharmaceuticals Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
897
- Stock Symbol
-
ANIP
- Investments
-
29
- Share Price
-
$62.12
- (As of Thursday Closing)
ANI Pharmaceuticals General Information
Description
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Contact Information
Website
www.anipharmaceuticals.comCorporate Office
- 210 Main Street West
- Baudette, MN 56623
- United States
Corporate Office
- 210 Main Street West
- Baudette, MN 56623
- United States
ANI Pharmaceuticals Timeline
ANI Pharmaceuticals Stock Performance
As of 12-Jun-2025, ANI Pharmaceuticals’s stock price is $62.12. Its current market cap is $1.34B with 21.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $62.12 | $62.78 | $52.50 - $77.00 | $1.34B | 21.7M | 396K | -$1.26 |
ANI Pharmaceuticals Financials Summary
As of 31-Mar-2025, ANI Pharmaceuticals has a trailing 12-month revenue of $674M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,954,783 | 1,658,796 | 1,243,981 | 957,468 |
| Revenue | 674,068 | 614,376 | 486,816 | 316,385 |
| EBITDA | 66,862 | 63,121 | 106,603 | 25,040 |
| Net Income | (21,048) | (18,522) | 18,779 | (47,896) |
| Total Assets | 1,292,428 | 1,283,697 | 904,422 | 760,087 |
| Total Debt | 622,822 | 624,092 | 285,669 | 286,519 |
ANI Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ANI Pharmaceuticals Comparisons
Industry
Financing
Details
ANI Pharmaceuticals Competitors (21)
One of ANI Pharmaceuticals’s 21 competitors is Taro Pharmaceutical Industries, a Corporate Backed or Acquired company based in Haifa Bay, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Taro Pharmaceutical Industries | Corporate Backed or Acquired | Haifa Bay, Israel | ||||
| Lannett Company | Corporation | Trevose, PA | ||||
| Breckenridge Pharmaceutical | Corporate Backed or Acquired | NJ | ||||
| Padagis | Private Equity-Backed | Allegan, MI | ||||
| Amneal Pharmaceuticals | Formerly PE-Backed | Bridgewater, NJ |
ANI Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ANI Pharmaceuticals Patents
ANI Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11975047-B1 | Methods for storing and warming purified corticotropin compositions | Active | 28-Oct-2022 | ||
| US-12102662-B1 | Methods for storing and warming purified corticotropin compositions | Active | 28-Oct-2022 | ||
| US-12133831-B1 | Kits for preparing and delivering purified corticotropin | Active | 28-Oct-2022 | ||
| US-12233105-B1 | Methods for storing and warming purified corticotropin compositions | Active | 28-Oct-2022 | ||
| US-12324787-B1 | Kits for preparing and delivering purified corticotropin | Active | 28-Oct-2022 | A61J1/1443 |
ANI Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ANI Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ANI Pharmaceuticals Investments & Acquisitions (29)
ANI Pharmaceuticals’s most recent deal was a Merger/Acquisition with Alimera Sciences for . The deal was made on 16-Sep-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Alimera Sciences | 16-Sep-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Alvogen (Certain Pharmaceutical Products Rights in Morristown, New Jersey) | 27-Dec-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Slayback Pharma (ANDA, Registered Patents and Patent Applications in Princeton, New Jersey) | 14-Aug-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Akorn (ANDA Assets) | 15-Jun-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Oakrum Pharma (Portfolio Four Abbreviated New Drug Applications) | 21-Jul-2022 | Corporate Asset Purchase | Buildings and Property |
ANI Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated January, 18, 2025
39 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
ANI Pharmaceuticals Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| ANI Pharmaceuticals Canada | Oakville, Canada | 2018 | |
| Novitium | East Windsor, NJ | 2016 | |
| Alimera Sciences | Alpharetta, GA | 2003 |
ANI Pharmaceuticals FAQs
-
When was ANI Pharmaceuticals founded?
ANI Pharmaceuticals was founded in 1996.
-
Where is ANI Pharmaceuticals headquartered?
ANI Pharmaceuticals is headquartered in Baudette, MN.
-
What is the size of ANI Pharmaceuticals?
ANI Pharmaceuticals has 897 total employees.
-
What industry is ANI Pharmaceuticals in?
ANI Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is ANI Pharmaceuticals a private or public company?
ANI Pharmaceuticals is a Public company.
-
What is ANI Pharmaceuticals’s stock symbol?
The ticker symbol for ANI Pharmaceuticals is ANIP.
-
What is the current stock price of ANI Pharmaceuticals?
As of 12-Jun-2025 the stock price of ANI Pharmaceuticals is $62.12.
-
What is the current market cap of ANI Pharmaceuticals?
The current market capitalization of ANI Pharmaceuticals is $1.34B.
-
What is ANI Pharmaceuticals’s current revenue?
The trailing twelve month revenue for ANI Pharmaceuticals is $674M.
-
Who are ANI Pharmaceuticals’s competitors?
Taro Pharmaceutical Industries, Lannett Company, Breckenridge Pharmaceutical, Padagis, and Amneal Pharmaceuticals are some of the 21 competitors of ANI Pharmaceuticals.
-
What is ANI Pharmaceuticals’s annual earnings per share (EPS)?
ANI Pharmaceuticals’s EPS for 12 months was -$1.26.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
